Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted Zr-89-Pertuzumab PET/CT

首页> 外文期刊>Radiology >Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted Zr-89-Pertuzumab PET/CT

【24h】

Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted Zr-89-Pertuzumab PET/CT

机译：使用Her2针对Zr-89-Pertuzumab PET / CT鉴定HER2阴性原发性乳腺癌患者HER2阳性转移的鉴定

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Human epidermal growth factor receptor 2 (HER2)-targeted therapies are successful in patients with HER2-positive malignancies; however, spatial and temporal heterogeneity of HER2 expression may prevent identification of optimal patients for these therapies.

机译：背景：人表皮生长因子受体2（HER2） - 患有Her2阳性恶性肿瘤的患者成功疗法; 然而，HER2表达的空间和时间异质性可以防止鉴定这些疗法的最佳患者。

著录项

来源
《Radiology》 |2020年第2期|共9页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类放射医学;
关键词

相似文献

外文文献
中文文献
专利

1. Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted Zr-89-Pertuzumab PET/CT [J] . Radiology . 2020,第2期

机译：使用Her2针对Zr-89-Pertuzumab PET / CT鉴定HER2阴性原发性乳腺癌患者HER2阳性转移的鉴定
2. Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using Zr-89-Trastuzumab PET/CT [J] . Ulaner Gary A., Hyman David M., Ross Dara S., The Journal of Nuclear Medicine . 2016,第10期

机译：使用Zr-89-曲妥珠单抗PET / CT检测HER2阴性原发性乳腺癌患者HER2阳性转移
3. Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT [J] . Gary A. Ulaner, David M. Hyman, Dara S. Ross, The Journal of Nuclear Medicine . 2016,第10期

机译：使用89Zr-曲妥珠单抗PET / CT检测HER2阴性原发性乳腺癌患者HER2阳性转移
4. Expression analysis and mass spectrometric structure characterization reveals unknown ezrin truncations in lymph node metastases of breast cancer patients [C] . Claudia Rower, Christian George, Toralf Reimer, ASMS Conference on Mass Spectrometry and Allied Topics . 2014

机译：表达分析和质谱结构表征揭示乳腺癌患者淋巴结转移中未知的Ezrin截短
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT [O] . Gary A. Ulaner, David M. Hyman, Dara S. Ross, -1

机译：使用89Zr-曲妥珠单抗PET / CT检测HER2阴性原发性乳腺癌患者HER2阳性转移
7. Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis [O] . Noman Paracha, Adriana Reyes, Véronique Diéras, 2020

机译：在先前治疗，不可切除或转移性HER2阳性乳腺癌患者之前，评估前紫杉烷/曲妥珠单抗后各种HER2针对性方案的临床效果和安全性：系统审查和网络META分析
8. F18 EF5 PET/CT Imaging in Patients with Brain Metastases from Breast Cancer. [R] . Lin, L. 2014

机译：F18 EF5 pET / CT显像对乳腺癌脑转移患者的影响。

Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted Zr-89-Pertuzumab PET/CT

摘要

著录项

相似文献

相关主题

期刊订阅